Clinical significance of chromosome 1p/19q loss of heterozygosity and Sox17 expression in oligodendrogliomas

International Journal of Clinical and Experimental Pathology

Volumn 7, Issue 12, 2014, Pages 8609-8615

  Li, Junzhi ^a   Miao, Na ^a   Liu, Ming ^a   Cui, Wenli ^a   Liu, Xia ^a   Li, Xinxia ^a   Shi, Xiaoli ^a   Qing, Song ^a   Ma, Yuqing ^a   Zhang, Wei ^a   Biekemituofu, Hadeti ^a  

^a XINJIANG MEDICAL UNIVERSITY   (China)

Author keywords

1p 19q LOH; Clinical features; Oligodendroglioma; Prognosis; Sox17

Indexed keywords

SOX17 PROTEIN, HUMAN; TRANSCRIPTION FACTOR SOX; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; BIOSYNTHESIS; BRAIN TUMOR; CHILD; CHROMOSOME 1; CHROMOSOME 19; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; HETEROZYGOSITY LOSS; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MALE; METABOLISM; MIDDLE AGED; MORTALITY; OLIGODENDROGLIOMA; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BIOMARKERS, TUMOR; BRAIN NEOPLASMS; CHILD; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 19; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; OLIGODENDROGLIOMA; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SOXF TRANSCRIPTION FACTORS; YOUNG ADULT;

EID: 84921443971     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P. World health organization classification of turnouts of the central nervous system. Acta Neuropathol 2007; 114: 97-109.
2. Fuller CE, Perry A. Molecular diagnostics in central nervous system tumors. Adv Anat Pathol 2005; 12: 180-94.
3. Jiang H, Ren X, Cui X, Wang J, Jia W, Zhou Z, Lin S. 1p/19q codeletion and IDH1/2 mutation identified a subtype of anaplastic oligoastrocytomas with prognosis as favorable as anaplastic oligodendrogliomas. Neuro Oncol 2013; 15: 775-82.
4. Zhang S, Li Y, Wu Y, Shi K, Bing L, Hao J. Wnt/ß-catenin signaling pathway upregulates c-Myc expression to promote cell proliferation of P19 teratocarcinoma cells. Anat Rec 2012; 295: 2104-13.
5. Schniederjan MJ, Alghamdi S, Castellano-Sanchez A, Mazewski C, Brahma B, Brat DJ, Brathwaite CD, Janss AJ. Diffuse leptomeningeal neuroepithelial tumor 9 pediatric cases with chromosome 1p/19q deletion status and IDH1 (R132H) immunohistochemistry. Am J Surg Pathol 2013; 37: 763-71.
6. Raghavan R, Balani J, Perry A, Margraf L, Vono MB, Cai DX, Wyatt RE, Rushing EJ, Bowers DC, Hynan LS, White CL 3rd. Pediatric oligodendrogliomas: a study of molecular alterations on 1p and 19q using fluorescence in situ hybridization. J Neuropath Exp Neurol 2003; 62: 530-7.
7. Myal Y, Del Bigio MR, Rhodes, RH. Age-related differences in 1p and 19q deletions in oligodendrogliomas. BMC Clin Path 2003; 3: 6.
8. Zlatescu MC, TehraniYazdi A, Sasaki H, Megyesi JF, Betensky RA, Louis DN, Cairncross JG. Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms. Cancer Res 2001; 61: 6713-5.
9. Mueller W, Hartmann C, Hoffmann A, Lanksch W, Kiwit J, Tonn J, Veelken J, Schramm J, Weller M, Wiestler OD, Louis DN, von Deimling A. Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. Am J Pathol 2002; 161: 313-9.
10. McDonald JM, See SJ, Tremont IW, Colman H, Gilbert MR, Groves M, Burger PC, Louis DN, Giannini C, Fuller G, Passe S, Blair H, Jenkins RB, Yang H, Ledoux A, Aaron J, Tipnis U, Zhang W, Hess K, Aldape K. The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors. Cancer 2005; 104: 1468-77.
11. Reifenberger G, Louis DN. Oligodendroglioma: towards molecular definitions in diagnostic neuro-oneology. J Neuro Pathol Exp Neurol 2003; 62: 111-26.
12. Boots-Sprenger SH, Sijben A, Rijntjes J, Tops BB, Idema AJ, Rivera AL, Bleeker FE, Gijtenbeek AM, Diefes K, Heathcock L, Aldape KD, Jeuken JW, Wesseling P. Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT promoter methylation in gliomas: use with caution. Mod Pathol 2013; 26: 922-9.
13. Sabha N, Knobbe CB, Maganti M, Al Omar S, Bernstein M, Cairns R, Çako B, von Deimling A, Capper D, Mak TW, Kiehl TR, Carvalho P, Garrett E, Perry A, Zadeh G, Guha A, Sidney Croul. Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas. Neuro Oncol 2014; 16: 914-23.
14. Intergroup Radiation Therapy Oncology Group Trial 94021, Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D, Buckner J, Fink K, Souhami L, Laperierre N, Mehta M, Curran W. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 2006; 24: 2707-2714.
15. van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ, Frenay M, Tijssen CC, Grisold W, Sipos L, Haaxma-Reiche H, Kros JM, van Kouwenhoven MC, Vecht CJ, Allgeier A, Lacombe D, Gorlia T. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: A randomized European Organisation for Resea-rch and Treatment of Cancer phase III trial. J Clin Oncol 2006; 24: 2715-22.
16. Jenkins RB, Blair H, Ballman KV, Giannini C, Arusell RM, Law M, Flynn H, Passe S, Felten S, Brown PD, Shaw EG, Buckner JC. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 2006; 66: 9852-61.
17. Sohn J, Natale J, Chew LJ, Belachew S, Cheng Y, Aguirre A, Lytle J, Nait-Oumesmar B, Kerninon C, Kanai-Azuma M, Kanai Y, Gallo V. Identification of Sox17 as a transcription factor that regulates oligodendrocyte development. J Neurousci 2006; 26: 9722-35.
18. Artus J, Piliszek A, Hadjantonakis AK. The primitive endoderm lineage of the mouse blastocyst: sequential transcription factor activation and regulation of differentiation by Sox17. Dev Biol 2011; 350: 393-404.
19. Zhang W, Glockner SC, Guo M, Machida EO, Wang DH, Easwaran H, Van Neste L, Herman JG, Schuebel KE, Watkins DN, Ahuja N, Baylin SB. Epigenetic inactivation of the canonical Wnt antagonist SRY-box containing gene 17 in colorectal cancer. Cancer Res 2008; 68: 2764-72.
20. Fu DY, Wang ZW, Li-Chen, Wang BL, Shen ZZ, Huang W, Shao ZM. Sox17, the canonical Wnt antagonist, is epigenetically inactivated by promoter methylation in human breast cancer. Breast Cancer Res Treat 2010; 119: 601-12.
21. Jia Y, Yang Y, Liu S, Herman JG, Lu F, Guo M. Sox17 antagonizes WNT/ß-catenin signaling pathway in hepatocellular carcinoma. Epigene-tics 2010; 5: 743-749.
22. Dong T, Yin. Epigenetic Changes of Sox17 in Lung Carcinoma and Functional Study. Beijing: Institute for advanced study in military medical; 2011.
23. Huag ZM, Zhang HY, Zhao G. Correlation between the expression of gene Sox17 and the cell migration, invasion power of hepatocarcinoma cells. Mod Oncol 2012; 12: 2457-60.